Home »
Academic Articles & Research Papers
Showing 20 of 25 academic articles
Chen X, Ni P, Li W, Wu M et al. • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1958538
PMC: PMC13732141
Chen A, Pulido JS, Tonne J, Metko M et al. • Cancer immunology research
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1158/2326-6066.CIR-25-1589
PMC: PMC13737429
Wang X, Wang Q, Gao W, He S et al. • Molecular cancer
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1186/s12943-026-02748-w
PMC: PMC13556080
Wang B, Zhao D, Ma Y, Sui C • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1954319
PMC: PMC13669672
Zhong D, Li C, Xiao Z • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1938564
PMC: PMC13697605
Han X, Yamashita K, Pizzi MP, Cho KS et al. • Journal for immunotherapy of cancer
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1136/jitc-2026-015653
PMC: PMC13723904
Huang J, Zhong H, Li L, Wang X et al. • Frontiers in oncology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fonc.2026.1962391
PMC: PMC13724477
Katja Niesel, Michael Schulz, Julian Anthes, Tijna Alekseeva et al. • EMBO Molecular Medicine
(2021)
Abstract The tumor microenvironment in brain metastases is characterized by high myeloid cell content associated with immune suppressive and cancer‐permissive functions. Moreover, brain metastases induce the recruitment of lymphocytes. Desp...
DOAJ
Open Access (DOAJ)
DOI: 10.15252/emmm.202013412
Shuping Wang, Pengcheng Chen, Xiaozhen Jing, Jinglin Zou et al. • Materials & Design
(2026)
STING agonist-based immunotherapy holds considerable promise for cancer treatment, yet its efficacy against immunologically “cold” tumors such as lung adenocarcinoma (LUAD) remains markedly limited. A major obstacle lies in the highly glyco...
DOAJ
Open Access (DOAJ)
DOI: 10.1016/j.matdes.2026.117182
Jing Ma, Ruijuan Ma, Xueke Zeng, Liming Zhang et al. • Journal of Experimental & Clinical Cancer Research
(2023)
Abstract Background Platinum-drugs based chemotherapy in clinic increases the potency of tumor cells to produce M2 macrophages, thus leading to poor anti-metastatic activity and immunosuppression. Lysosome metabolism is critical for cancer ...
DOAJ
Open Access (DOAJ)
DOI: 10.1186/s13046-023-02768-0
Yujun Cai, Gengjia Chen, Minzhao Lin, Bo Li et al. • Aggregate
(2024)
Abstract Nanodrugs capable of aggregating in the tumor microenvironment (TME) have demonstrated great efficiency in improving the therapeutic outcome. Among various approaches, the strategy utilizing electrostatic interaction as a driving f...
DOAJ
Open Access (DOAJ)
DOI: 10.1002/agt2.476
Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi • BioImpacts
(2019)
Introduction: Triple-negative breast cancer (TNBC) is an important subtype of breast cancer, which occurs in the absence of estrogen, progesterone and HER-2 receptors. According to the recent studies, TNBC may be a cancer testis antigen (CT...
DOAJ
Open Access (DOAJ)
DOI: 10.15171/bi.2019.06
Bin Zhao, Sa Chen, Ye Hong, Liangliang Jia et al. • Pharmaceutics
(2022)
The conventional cancer therapeutic modalities include surgery, chemotherapy and radiotherapy. Although immunotherapy and targeted therapy are also widely used in cancer treatment, chemotherapy remains the cornerstone of tumor treatment. Wi...
DOAJ
Open Access (DOAJ)
DOI: 10.3390/pharmaceutics14071522
Jing Sun, Jing Wang, Xin Jiang, Jing Xia et al. • BMC Biology
(2024)
Abstract Background The intracellular bacterium Listeria monocytogenes is an attractive vector for cancer immunotherapy as it can effectively deliver tumor antigens to antigen-presenting cells, leading to a robust antitumor response. Result...
DOAJ
Open Access (DOAJ)
DOI: 10.1186/s12915-024-02086-7
Patrick Leo, Hauke Kolster, Hartmut Koeppen, Jennifer Giltnane et al. • Journal of Pathology Informatics
(2026)
Whereas anti-PD-(L)1 therapies are widely used in cancer treatment, only a subset of patients achieve long-term survival. Companion diagnostics based on PD-L1 expression have limited predictive power for these therapies, motivating developm...
DOAJ
Open Access (DOAJ)
DOI: 10.1016/j.jpi.2026.100688
Dan Lu, Yuan Chen, Min Jiang, Jie Wang et al. • Nature Communications
(2023)
Abstract KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to el...
DOAJ
Open Access (DOAJ)
DOI: 10.1038/s41467-023-42010-1
Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer
(2024)
Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...
DOAJ
Open Access (DOAJ)
DOI: 10.1136/jitc-2023-008450
Sophia Daum, Lilith Decristoforo, Mira Mousa, Stefan Salcher et al. • Molecular Cancer
(2025)
Abstract The dynamic interactions between tumor endothelial cells (TECs) and the immune microenvironment play a critical role in the progression of non-small cell lung cancer (NSCLC). In general, endothelial cells exhibit diverse immunomodu...
DOAJ
Open Access (DOAJ)
DOI: 10.1186/s12943-024-02221-6
Ziqiang Wang, Jing Zhang, Huili Chen, Xinyu Zhang et al. • Frontiers in Immunology
(2025)
BackgroundM2-like tumor-associated macrophages (TAMs) promote an immunosuppressive microenvironment and contribute to tumor progression and metastasis. However, their molecular characterization and prognostic value have not been fully explo...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fimmu.2025.1650726
Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena et al. • Frontiers in Immunology
(2025)
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successe...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fimmu.2024.1489827